PS12(PM) Position statement on the use of ketamine in the management of chronic non-cancer pain
ANZCA_2022-Aus-Gov-Federal-election-priorities_P2
PS12(PM)BP Position Statement on the use of ketamine in the management of CNCP Background paper
ANZCA Annual Report 2020 (full financials)
ANZCA Annual Report 2020 (full financials)
8-Specific-clinical-situations-Watermarked
FPM Procedures Endorsement Program Curriculum
2-0-Assessment-Watermarked
FPM by-law 16 - Recognition as a specialist (SIMG)
Intellectual property policy